



**ISOGENICA MULTI-YEAR MULTI-TARGET COLLABORATION WITH ARO BIOTHERAPEUTICS EXTENDED  
Cambridge, UK. January 18<sup>th</sup>, 2020**

Isogenica Ltd, a leader in the use of synthetic biology and in vitro display for the discovery and optimisation of novel biotherapeutics, announced today that it has extended its multi-year, multi-target collaboration and license agreement with Aro Biotherapeutics.

The expansion builds on a successful partnership initiated in 2018, under which Isogenica has been responsible for the identification and characterisation of Centyrins against target antigens. These human proteins have been engineered to have unique properties that make them ideally suited to target receptors on specific cells and deliver complex drug payloads to specific disease sites.

Isogenica's Director of Alliances, Dr Bill Eldridge, said: "Aro is pursuing innovative science including previously undruggable targets where the internalisation of payloads will be critical for therapeutic success. I'm delighted we've been successful in delivering key outcomes to help build Aro's growing therapeutics pipeline".

"Aro Biotherapeutics' successful collaboration with Isogenica is a great example of two companies with complementary expertise and technologies coming together to accelerate the development of novel tissue-specific targeting therapeutics" said Dr Karyn O-Neil, co-founder and CSO of Aro Biotherapeutics.

**About Isogenica**

Isogenica is an antibody discovery biotechnology company specialising in single-domain antibody therapeutics. These small format antibodies can be readily incorporated into gene and cell therapies, antibody-drug conjugates and bi- and multi-specific antibody therapeutics making them a highly versatile platform for drug development. The company's fully synthetic single domain library is designed from the DNA up, to eliminate liabilities and improve the biophysical traits of library antibodies. Combined with CIS Display, Isogenica's proprietary antibody display platform which enables the full diversity of the company's massive libraries to be displayed, the company has a unique and proven engine for therapeutic antibody discovery and development. Working in collaboration with biopharmaceutical partners over the last decade the company has developed a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.

For more information, visit: [www.isogenica.com](http://www.isogenica.com)

**Contact:**

Mandeep Sehmi, Associate Director Marketing

T: +44 1799 533 680

E: [mandeep.sehmi@isogenica.com](mailto:mandeep.sehmi@isogenica.com)

**About Aro Biotherapeutics**

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. For more information, visit [www.arobiotx.com](http://www.arobiotx.com).